Month: October 2022

On April 25, 2013, Connolly, Peter J.; Bian, Haiyan; Li, Xun; Liu, Li; Macielag, Mark J.; McDonnell, Mark E. published a patent.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate The title of the patent was Preparation of piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors. And the patent contained the following:

The title compounds I [Y and Z = (un)substituted aryl, heteroaryl, 1,3-dihydro-3H-benzimidazol-2-on-yl, etc.; R = H or OH], useful for treating various diseases, syndromes, conditions and disorders, including pain, were prepared E.g., a multi-step synthesis of II, starting from tert-Bu 3-iodoazetidine-1-carboxylate, was described. Exemplified compounds I were tested in the MGL activity assay (data given). Pharmaceutical composition comprising compound I is disclosed. The experimental process involved the reaction of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate(cas: 1251006-64-0).Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

The Article related to piperidinylazetidine diamide amide preparation monoacylglycerol lipase inhibitor analgesic, inflammatory pain treatment piperidinylazetidine amide preparation monoacylglycerol lipase inhibitor and other aspects.Safety of tert-Butyl 3-(piperidin-4-yl)azetidine-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On October 1, 2017, Schwalbe, Tobias; Kaindl, Jonas; Huebner, Harald; Gmeiner, Peter published an article.COA of Formula: C11H14ClNO The title of the article was Potent haloperidol derivatives covalently binding to the dopamine D2 receptor. And the article contained the following:

The dopamine D2 receptor (D2R) is a common drug target for the treatment of a variety of neurol. disorders including schizophrenia. Structure based design of subtype selective D2R antagonists requires high resolution crystal structures of the receptor and pharmacol. tools promoting a better understanding of the protein-ligand interactions. Recently, we reported the development of a chem. activated dopamine derivative (FAUC150) designed to covalently bind the L94C mutant of the dopamine D2 receptor. Using FAUC150 as a template, we elaborated the design and synthesis of irreversible analogs of the potent antipsychotic drug haloperidol forming covalent D2R-ligand complexes. The disulfide- and Michael acceptor-functionalized compounds showed significant receptor affinity and an irreversible binding profile in radioligand depletion experiments The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).COA of Formula: C11H14ClNO

The Article related to preparation haloperidol derivative covalently binding dopamine d2 receptor, chemical probe, covalent ligand, disulfide tethering, dopamine d(2) receptor, g protein-coupled receptor, haloperidol and other aspects.COA of Formula: C11H14ClNO

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 27, 2006, Burgey, Christopher S.; Paone, Daniel V.; Shaw, Anthony W.; Nguyen, Diem N.; Deng, Zhengwu J.; Williams, Theresa M.; Vacca, Joseph P.; Selnick, Harold G.; Potteiger, Craig M. published a patent.Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate The title of the patent was Imidazolo[1,2-a]azepane and triazolo[4,3-a]azepane derivatives as CGRP receptor antagonists and their preparation, pharmaceutical compositions, and use for treatment of diseases in which CGRP is involved such as headache, migraine and cluster headache. And the patent contained the following:

Compounds of formula I and formula II are useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. Compounds of formula I and II wherein Z is (un)substituted piperidine or (un)substituted spiropiperidine; A is C(R2)2, O, SOm, or NR2; B is [C(R2)2]n; D is N or CR1; R1 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-6 cycloalkyl, (un)substituted heterocyclyl, or (un)substituted (hetero)aryl; each R2 is independently H, (un)substituted C0-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-6 cycloalkyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl; any two R2 on the same or adjacent atoms optionally join to form cycloalkyl, (hetero)aryl, or heterocycloalkyl ring; W is O, NR4 or C(R4)2; R4 is H, (un)substituted (fluoro)C1-6 alkyl, (un)substituted C3-6 cycloalkyl, and (un)substituted (hetero)aryl, or benzyl; X is C or S; Y is O, (R4)2, NCN, NSO2Me or NCONH2; or Y is O2 when X is S; m is O, 1, or 2; n is 1 or 2; and pharmaceutically acceptable salts and diastereoisomers thereof are claimed in this invention. Example compound III was prepared by condensation of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-thioxoazepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide with 1-amino-3-methylbutan-2-ol to give N-[(3R,6S)-6-(2,3-difluorophenyl)-2-[(2-hydroxy-3-methylbutyl)imino]azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide TFA salt, which underwent oxidation to give example compound III. All the invention compounds were evaluated for their activity as antagonists of the CGRP receptor. From the assay, the example compounds, in general, exhibited Ki or IC50 values of less than about 50 μM. The experimental process involved the reaction of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate(cas: 883984-95-0).Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

The Article related to imidazoloazepane triazoloazepane preparation pharmaceutical composition cgrp receptor antagonist, triazoloazepane imidazoloazepane preparation treatment headache migraine cgrp receptor antagonist and other aspects.Quality Control of Benzyl 7′-chloro-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3-d][1,3]oxazine]-1-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 27, 2001, Duan, Jingwu; King, Bryan W.; Decicco, Carl; Maduskuie, Thomas P., Jr.; Voss, Matthew E. published a patent.Electric Literature of 362703-57-9 The title of the patent was Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α. And the patent contained the following:

Novel β-amino acid derivatives A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.; R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepared as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepared by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Electric Literature of 362703-57-9

The Article related to amino acid beta preparation inhibitor metalloprotease tnf, heterocyclyl beta amino acid preparation inhibitor metalloprotease tnf, cycloalkyl beta amino acid preparation inhibitor metalloprotease tnf and other aspects.Electric Literature of 362703-57-9

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 15, 2004, Duan, Jingwu; King, Bryan W.; Decicco, Carl; Maduskuie, Thomas P.; Voss, Mathew E. published a patent.Electric Literature of 362703-57-9 The title of the patent was Preparation of β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α. And the patent contained the following:

Novel β-amino acid derivatives A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.; R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepared as metalloprotease and TNF-α inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepared by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Electric Literature of 362703-57-9

The Article related to amino acid beta preparation inhibitor metalloprotease tnf, heterocyclyl beta amino acid preparation inhibitor metalloprotease tnf, cycloalkyl beta amino acid preparation inhibitor metalloprotease tnf and other aspects.Electric Literature of 362703-57-9

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On January 27, 2015, Sozio, Piera; Fiorito, Jole; Di Giacomo, Viviana; Di Stefano, Antonio; Marinelli, Lisa; Cacciatore, Ivana; Cataldi, Amelia; Pacella, Stephanie; Turkez, Hasan; Parenti, Carmela; Rescifina, Antonio; Marrazzo, Agostino published an article.Computed Properties of 39512-49-7 The title of the article was Haloperidol metabolite II prodrug: Asymmetric synthesis and biological evaluation on rat C6 glioma cells. And the article contained the following:

In a previous work the authors reported the antiproliferative effects of (±)-MRJF4, a novel haloperidol metabolite II (HP-mII) (a sigma-1 antagonist and sigma-2 agonist) prodrug, obtained through conjugation to 4-phenylbutyric acid (PhBA) [a histone deacetylase inhibitor (HDACi)] by an ester bond. As a continuation of this work, here the authors report the asym. synthesis of compounds Benzenebutanoic acid 4-[(1R)-4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)butyl ester [(R)-(+)-MRJF4] and 4-[(1R)-4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)butyl ester [(S)-(-)-MRJF4] and the evaluation of their biol. activity on rat C6 glioma cells, derived from glioblastoma multiforme (GBM), which is the most common and deadliest central nervous system (CNS) invasive malignancy. Favorable physicochem. properties, high permeability in the parallel artificial membrane permeability assay (PAMPA), good enzymic and chem. stability, in vivo anticancer activity, associated with the capacity to reduce cell viability and to increase cell death by apoptosis, render compound (R)-(+)-MRJF4 a promising candidate for the development of a useful therapeutic for glioma therapy. The synthesis of the target compounds was achieved by a reaction of (αS)-4-(4-chlorophenyl)-α-(4-fluorophenyl)-4-hydroxy-1-piperidienbutanol or (αR)-4-(4-chlorophenyl)-α-(4-fluorophenyl)-4-hydroxy-1-piperidienbutanol with benzenebutanoyl chloride. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Computed Properties of 39512-49-7

The Article related to haloperidol metabolite prodrug anticancer antitumor glioma, benzenebutanoic acid hydroxypiperidine preparation anticancer agent cns glioma, glioma, hdac, inhibitors, medicinal chemistry, sigma receptors and other aspects.Computed Properties of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On January 23, 2020, Accetta, Alessandro; Rancati, Fabio; Capelli, Anna Maria; Clark, David Edward; Tisselli, Patrizia; Edwards, Christine; Cheguillaume, Arnaud Jean Francois Auguste; Bhalay, Gurdip published a patent.Name: 4-Benzenesulfonylpiperidine Hydrochloride The title of the patent was Preparation of tyrosine amide derivatives as Rho-kinase inhibitors. And the patent contained the following:

The invention relates to compounds of formula I and pharmaceutically acceptable salts and solvates thereof, wherein X1 and X2 are independently CH and N; p = 1 – 3; each R when present is halo; R0 and R1 are independently H, halo, CN, etc.; R2 and R3 are independently H, C1-6 alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl; R4 and R5 are independently H, C1-6 alkyl;R6 is H, alkyl, haloalkyl; were prepared and used as Rho kinase inhibitors. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). Example compound II was prepared. The invention compounds were evaluated for their Rho-associated protein kinase ROCK1 and ROCK2 inhibitory activities. From the assay, it was determined that compound II exhibited Ki value of < 3 nM. The experimental process involved the reaction of 4-Benzenesulfonylpiperidine Hydrochloride(cas: 1172500-91-2).Name: 4-Benzenesulfonylpiperidine Hydrochloride

The Article related to human, asthma chronic obstructive pulmonary idiopathic fibrosis hypertension, rho kinase inhibitor tyrosine amide amino acid preparation copd, tyrosine amide rho kinase inhibitor preparation rock1 rock2 pulmonary and other aspects.Name: 4-Benzenesulfonylpiperidine Hydrochloride

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 19, 2022, Zhang, Ke; Ren, Bai-Hao; Liu, Xiao-Fei; Wang, Lin-Lin; Zhang, Min; Ren, Wei-Min; Lu, Xiao-Bing; Zhang, Wen-Zhen published an article.Product Details of 39512-49-7 The title of the article was Direct and Selective Electrocarboxylation of Styrene Oxides with CO2 for Accessing β-Hydroxy Acids. And the article contained the following:

Highly selective and direct electroreductive ring-opening carboxylation of epoxides with CO2 in an undivided cell was reported. This reaction showed broad substrate scopes within styrene oxides under mild conditions, providing practical and scalable access to important synthetic intermediate β-hydroxy acids. Mechanistic studies show that CO2 functions not only as a carboxylative reagent in this reaction but also as a promoter to enable efficient and chemoselective transformation of epoxides under additive-free electrochem. conditions. Cathodically generated α-radical and α-carbanion intermediates leaded to the regioselective formation of α-carboxylation products. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Product Details of 39512-49-7

The Article related to epoxide carbon dioxide regioselective chemoselective electroreductive ring opening carboxylation, hydroxyalkyl carboxylic acid preparation, carbon dioxide fixation, carboxylation, epoxides, hydroxy acids, organic electrosynthesis and other aspects.Product Details of 39512-49-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On April 22, 2004, King, Bryan W.; Sheppeck, James; Gilmore, John L. published a patent.Recommanded Product: 362703-57-9 The title of the patent was Preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents. And the patent contained the following:

The present application describes novel hydantoin derivatives (shown as I; A = O, S; L-R11 represents a very large variety of substituents and is defined in the claims; e.g. II) or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof. Some examples of I exhibit Ki’s <10 μM but individual data are not presented. Although the methods of preparation are not claimed, 37 example preparations are included. For example, II was prepared in 4 steps (100, 66, 73 and 82%, resp.) starting with condensation of Et 4-aminobutyrate hydrochloride with 4-(2-methylquinolin-4-ylmethoxy)benzoyl chloride hydrochloride followed by base hydrolysis to the acid, followed by hydrazide formation with thiosemicarbazide followed by cyclization. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Recommanded Product: 362703-57-9

The Article related to triazolone triazolethione preparation inhibitor matrix metalloproteinase tace antiinflammatory, tnf alpha converting enzyme inhibitor triazolone triazolethione preparation, aggrecanase inhibitor triazolone triazolethione preparation and other aspects.Recommanded Product: 362703-57-9

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

On September 30, 2020, Szczukowski, Lukasz; Redzicka, Aleksandra; Wiatrak, Benita; Krzyzak, Edward; Marciniak, Aleksandra; Gebczak, Katarzyna; Gebarowski, Tomasz; Swiatek, Piotr published an article.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol The title of the article was Design, synthesis, biological evaluation and in silico studies of novel pyrrolo[3,4-d]pyridazinone derivatives with promising anti-inflammatory and antioxidant activity. And the article contained the following:

Novel Mannich base analogs of pyrrolo[3,4-d]pyridazinone I (R1 = n-Bu, Ph; X = N, O, C; R2 = Ph, 4-MeC6H4, 2-pyridyl, etc.; R3 = OH) are designed and synthesized as potential anti-inflammatory agents. The title compounds are obtained via convenient one-pot synthesis with good yields. The aim of this study is to evaluate the inhibitory activity of the new derivatives against both cyclooxygenase isoforms COX1 and COX2 as well as their cytotoxicity. The results clearly indicate that the tested compounds are not toxic, all show better affinity towards isoform COX-2, and some of them act as selective COX-2 inhibitors. Moreover, every examined compounds I demonstrates better inhibitory activity towards COX-2 and a superior COX-2/COX-1 selectivity ratio compared to the reference drug meloxicam. Mol. docking studies confirm that all compounds preferably bind COX-2 and all of them bind to the active site of cyclooxygenase in a way very similar to meloxicam. Subsequently, synthesized Mannich bases are evaluated for potential antioxidant activity. Most of the investigated derivatives reduce induced oxidative and nitrosative stress. Moreover, some compounds protect chromatin from oxidative stress and decrease the number of DNA strand breaks caused by intracellular growth of free radicals. Finally, a study of the binding mechanism between compounds I and bovine serum albumin (BSA) was carried out and all examined derivatives interact with BSA, which suggests their potential long half-life in vivo. The experimental process involved the reaction of 4-(4-Chlorophenyl)piperidin-4-ol(cas: 39512-49-7).Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

The Article related to pyrrolopyridazinone preparation antiinflammatory antioxidant drug toxicity mol docking sar, 1,3,4-oxadiazole-2-thione, anti-inflammatory agents, antioxidants, cyclooxygenase inhibitors, mannich bases, molecular docking, pyridazinone and other aspects.Application In Synthesis of 4-(4-Chlorophenyl)piperidin-4-ol

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem